Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy

BACKGROUND: Gemcitabine/Cisplatin (Gem/CDDP) combination has demonstrated a clear survival advantage over gemcitabine alone and has become a new standard in advanced Biliary Tract Carcinoma (aBTC). However, Gemcitabine/Oxaliplatin (GEMOX) combination and Gemcitabine/Carboplatin (Gem/Carb) combinatio...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMC Gastroenterol
Glavni autori: Fiteni, Frédéric, Jary, Marine, Monnien, Franck, Nguyen, Thierry, Beohou, Eric, Demarchi, Martin, Dobi, Erion, Fein, Francine, Cleau, Denis, Fratté, Serge, Nerich, Virginie, Bonnetain, Franck, Pivot, Xavier, Borg, Christophe, Kim, Stefano
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4236575/
https://ncbi.nlm.nih.gov/pubmed/25117717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-230X-14-143
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items